• Clinical data 90%
  • Efficacy 80%
  • Security 70%
  • Toxicity 30%

Sabal serrulata 
Fructus Serenoae Repentis

Synonyms

Brahea serrulata (Michx.) H. Wendl., Chamaerops serrulata Michx., Corypha repens Bartr., Sabal serrulata (Michx.) Nichols, Sabal serrulata (Michx.) Nuttall. ex Schult., Serenoa serrulata Hook., Serenoa serrulata Roem. et Schult., Serenoa serrulatum (Michx.) Benth et Hook, Serenoa serrulatum Schult.

General appearance

Drupe superior, ellipsoidal, ovoid or somewhat globular, 1.5–3.0cm long, 1.0–1.5 cm in diameter; dark brown to black with a smooth, dull surface, somewhat oily, with a few large, angular depressions and ridges due to contraction of the inner layer on drying; summit marked by remains of style; base marked by stem-scars or has remains of stem. Epicarp and sarcocarp together form a thin coriaceous shell enclosing a hard but thin endocarp; endocarp externally reddish-brown and somewhat fibrous, as is inner layer of the sarcocarp; inner layer of endocarp smooth, enclosing an ellipsoidal or ovoid, hard somewhat flattened, anatropous, reddish-brown seed marked on the raphe side by anarillus-like appendage and marked on the opposite side near the end by the micropyle, which forms a slight projection; has a large endosperm of thickwalled parenchyma and a very small embryo at the micropyle.

Major chemical constituents

The major constituents are free fatty acids and their corresponding ethyl esters; sterols and lipids. The primary fatty acid constituents include oleic, lauric, myristic, palmitic, linoleic, caphoic, caprylic, capric, palmitoleic, stearic and linolenic acids. The major sterols include b-sitosterol, stigmasterol and daucosterol. The lipids consist of triglycerides of fatty acids.

Medicinal uses of Sabal serrulata

Uses supported by clinical data
Treatment of lower urinary tract symptoms (nocturia, polyuria, urinary retention) secondary to BPH stages I and II, as defined by Alken, in cases where diagnosis of prostate cancer is negative.
Uses described in pharmacopoeias and in traditional systems of medicine
As a diuretic and to treat an enlarged prostate.
Uses described in folk medicine, not supported by experimental or clinical data
As an aphrodisiac, a sedative and a nutritional tonic, as well as for the treatment of bronchitis, cystitis, dysmenorrhoea, sore throat and the common cold.

Pharmacology

Experimental pharmacology

Antispasmodic activity

Both lipid and saponifiable fractions of Fructus Serenoae Repentis reduced norepinephrine-induced contractions in vitro of rat aorta (IC50 0.53 and 0.50 mg/ml, respectively), as well as potassium chloride-induced contractions of rat uterus (EC50 0.35 and 0.43 mg/ml, respectively) (34). A 90% ethanol extract of the fruit reduced vanadate-induced contractions of the rat uterus (EC50 11.41mg/ml). Norepinephrine-induced contractions of rat deferential duct, and potassium chloride-induced contractions of guinea-pig ileum and bladder smooth muscle tissue were reduced by the addition of a 90% ethanol extract of the fruit (0.33 and 0.15 mg/ml, respectively).

Anti-inflammatory activity

Intragastric administration of an ethanol extract of the fruit to rats (5.0 g/kg body weight) inhibited carrageenan-induced footpad oedema. External application of a 90% ethanol extract of the fruit (500mg) to mice inhibited croton oil-induced ear oedema by 42%. Intragastric administration of an n-hexane extract of the fruit to rats (10ml/kg body weight) decreased capillary permeability induced by histamine, compound 48/80 and dextran, and generalized oedema induced by dextran. A carbon dioxide (supercritical) extract of the fruit inhibited cyclooxygenase and 5-lipoxygenase in vitro (IC50 28.1 and 18.0mg/ml, respectively). A lipidosterolic extract of the fruit inhibited the in vitro production of leukotriene B4 in human polymorphonuclear neutrophils stimulated with the calcium ionophore A23187. An ethanol extract of the fruit also suppressed A23187-stimulated synthesis of leukotriene B4 (IC50 8.3mg/ml) and thromboxane B2 (IC50 15.4mg/ml) in rat peritoneal leukocytes in vitro.

Immunostimulatory activity

Intraperitoneal administration of a polysaccharide fraction, isolated from an aqueous extract of the fruit, to mice (10mg/kg body weight) had immunostimulant activity, as measured by the colloidal carbon clearance test. An increased rate of phagocytosis by human polymorphonuclear leukocytes was observed in cells treated with a polysaccharide fraction of the extract (10mg/ml).
Anti-gonadotropic effects n-Hexane extracts of the fruit had anti-androgenic and anti-estrogenic activity in vitro. Dihydrotestosterone and testosterone uptake by cytosolic androgen receptors of human foreskin and other tissues was inhibited by 40.9% and 41.9%, respectively, after treatment of the tissues with the extract. In another study, the binding of [3H]dihydrotestosterone to both cytosolic and nuclear androgen receptors in cultured  human foreskin fibroblasts was inhibited by 90% and 70%, respectively, after treatment of the cells with  a sterol fraction of the n-hexane extract (IC50 7.1 units/ml). An n-hexane fruit extract inhibited androgen binding to cytosolic androgen receptors of rat prostatic tissue in a specific and competitive manner (IC50 330.0–367.5mg/ml). However, in contrast to these findings, the same extract did not inhibit the binding of [3H]dihydrotestosterone to androgen receptors in cultured human foreskin fibroblasts. Oral administration of an n-hexane extract (160 mg/day) inhibited the binding of 3H-labelled 17b-estradiol to the nuclear estrogen receptors in samples of prostatic tissue from patients with BPH. Binding to the cytosolic and nuclear estrogen and androgen receptors was measured by saturation analysis and an enzyme-linked immunosorbent assay.
The effect of an n-hexane extract of the fruit was evaluated in two human prostatic cell lines, LNCaP and PC3, which are respectively responsive and unre-sponsive to androgen stimulation. The extract (100mg/ml) induced proliferation and differentiation in LNCaP cells, but not in PC3 cells, suggesting that the androgen receptor plays a role in mediating the effects of the fruit in LNCaP cells. In PC3 cells cotransfected with genes for wild-type androgen receptor and a chloramphenicol acetyltransferase reporter under the control of an androgenresponsive element, the extract (25mg/ml) inhibited androgen-induced chloramphenicol acetyltransferase transcription by 70%.
n-Hexane, 90% ethanol and supercritical carbon dioxide extracts of the fruit inhibited 5a-reductase activity in vitro (37, 43, 46, 49–53). A lipidosterolic extract of the fruit (100mg/ml) inhibited 5a-reductase activity in the rat ventral prostate by 50%, and reduced conversion of testosterone into dihydrotestosterone in human foreskin fibroblasts by 90%. The conversion of dihydrotestosterone to 5a-androstane-3a 17b-diol by 3a-ketosteroid oxidoreductase was also partially inhibited in cultured human foreskin fibroblasts. An n-hexane extract of the fruit inhibited the activity of both 5areductase and 17b-hydroxysteroid dehydrogenase in cultures of epithelial cells (IC50 60 and 40mg/ml, respectively) and fibroblast cells (IC50 30 and 200mg/ml, respectively) obtained from the prostates of patients with BPH. One study reported no effect of several lipidosterolic extracts of the fruit on the activity of 5a-reductase from human prostate or on dihydrotestosterone binding to the rat prostatic androgen receptors at concentrations up to 100mg/ml. The reasons for these conflicting results are unclear, and may be due to the different methodologies used. Recently, it has been demonstrated that human 5areductase has two isoforms, type 1 and type 2; finasteride, a testosterone 5a-reductase inhibitor has been shown to be a selective inhibitor of the type 2 isoform (inhibitory concentration [Ki] 7.3 nmol/l). Furthermore, an n-hexane extract of the fruit was a non-competitive inhibitor of the type 1 isoform (IC50 7.2mg/ml) and an uncompetitive inhibitor of type 2 (IC50 4.9mg/ml). A 90% ethanol extract of the fruit showed a dose-dependent inhibition of 5areductaseactivity in the epithelium (29% inhibition) and stroma (45% inhibition) of prostate tissue from patients with BPH. When the extract was fractionated into saponifiable, non-saponifiable and hydrophilic subfractions, only the saponifiable subfraction (consisting mainly of lauric, oleic, myristic and palmitic acids) was active. Of these fatty acids, lauric acid was the most active: it inhibited epithelial and stromal 5a-reductase activity by 51% and 42%, respectively. The inhibition by lauric acid was noncompetitive and dosedependent up to a concentration of 0.2 mmol/l. The nonsaponifiable fraction, consisting mainly of phytosterols, was weakly active, while the hydrophilic subfractions, containing carbohydrates, amino acids and polysaccharides, were inactive. A supercritical extract of the fruit inhibited 5a-reductase activity in homogenates of cultured human foreskin fibroblasts (IC50 0.025 mg/ml).
One study compared testosterone metabolism in primary cultures of epithelial cells and fibroblasts obtained from the prostates of patients with BPH and prostate cancer. In all cultures, androst-4-ene-3,12-dione, formed by the oxidation of testosterone by 17b-hydroxysteroid dehydrogenase, accounted for 80% of all metabolites recovered. An n-hexane extract of the fruit inhibited the formation of androst-4-ene 3,12-dione in both cell types, indicating that it inhibited the activity of 17b-hydroxysteroid dehydrogenase, unlike finasteride, which was inactive.
An increase in the activity of 3a-hydroxysteroid-oxidoreductase (the enzyme that metabolizes dihydrotestosterone into the inactive androstenediol form) in prostate tissue from patients with BPH was reported following treatment of patients with an n-hexane extract of the fruit (320 mg daily for 3 months). Analysis of enzyme kinetics showed that the Vmax of 3-hydroxysteroid-oxidoreductase was significantly enhanced in the prostate stroma of treated patients. Since 3-hydroxysteroid-oxidoreductase also has a strong substrate affinity for prostaglandins, increased activity of the enzyme may also increase the metabolism of prostaglandins, thereby accounting for the reduction of prostaglandinmediated congestion or intraprostatic oedema formation.
Intragastric administration of an n-hexane extract of the fruit to castrated rats for 60–90 days inhibited the increase in total weight of the prostate induced by estradiol and testosterone. Intragastric administration of a 90% ethanol extract to castrated rats (6 ml/kg body weight, weekly for 8 weeks) inhibited the increase in weight of the ventral prostate, seminal vesicles and coagulation glands induced by testosterone. Intragastric administration of a 90% ethanol extract of the fruit inhibited prostate growth stimulated by both estradiol and dihydrotestosterone in nude mice into which prostate tissue from humans with BPH had been transplanted. An n-hexane extract of the fruit (30mg/ml) inhibited the proliferation of human prostate cells induced by basic fibroblast growth factor. Lupenone, hexacosanol and an unsaponified fraction of the extract markedly inhibited the proliferation of human prostate cells induced by basic fibroblast growth factor, but had only a minimal effect on basal cell proliferation.

Effects on signal transduction

Addition of an n-hexane extract of the fruit (1–10mg/ml) to Chinese hamster ovary cells completely inhibited the effects of prolactin on potassium conductance, protein kinase C activity and intracellular concentrations of calcium. These results suggest that the extract may inhibit prolactin-induced prostatic growth by interfering with the transduction signals involving the prolactin receptor. Lipidosterolic extracts of the fruit noncompetitively inhibited radioligand binding to human prostatic a1-adrenoceptors and agonist-induced [3H]inositol phosphate formation.

Clinical pharmacology

Placebo-controlled clinical trials

Eleven double-blind, placebo-controlled studies have assessed the effects of lipidosterolic extracts of Fructus Serenoae Repentis in the symptomatic treatment of mild to moderate BPH. The number of patients in each study ranged from 22 to 205, and the dosage of the extract was generally 160mg twice daily for 1–3 months. All but one study reported that the extract was significantly more effective than placebo in reducing the symptoms of mild to moderate BPH. In this study of 70 patients, which was also randomized, although a significant improvement in flow rate was seen in patients treated with either a hexane extract of the fruit (320 mg) or placebo daily for 3 months, no significant difference between the treatment groups was observed.
However, most studies demonstrated an increase in urinary flow rate and a decrease in postvoid residual urine volume. In another study which was also randomized, 205 patients were treated with 320 mg extract or placebo daily for 3 months. The study concluded that the extract was superior to placebo in reducing the total symptom score (polyuria, nocturia, dysuria, and urgency and hesitancy of micturition), improving the quality of life score, and increasing urinary volume.
A study was performed on 176 patients with BPH who had been unresponsive to placebo treatment in previous clinical studies. After 30 days of treatment with an extract of the fruit (160 mg, twice daily), there was a significant reduction in dysuria, polyuria and nocturia in the treated group as compared with the placebo group. Patients treated with the extract had a significantly greater increase in mean peak urinary flow rate (28.9%), as compared with those that received the placebo (8.5%), and the overall efficacy of the extract was rated higher than that of the placebo by both patients and physicians.
Another double-blind, placebo-controlled study assessed the effect of a lipidosterolic extract in the reduction of prostate oedema and congestion in 18 patients with BPH. Histopathological analysis of enucleated prostate tissue from patients treated preoperatively with the extract (320mg daily for 12 weeks) showed a significant decrease in prostate stromal oedema and congestion in treated patients, as compared with those in the placebo group (P  0.05).

Controlled clinical trials

In a controlled clinical trial, 25 men with symptoms of urinary obstruction were randomized into two groups: 15 patients received no treatment, while 10 were treated with an n-hexane extract of Fructus Serenoae Repentis (320 mg extract daily). After 3 months, prostatic specimens were removed by suprapubic prostatectomy and were sectioned into three regions (i.e. periurethral, subcapsular and intermediate). In each region, the concentration of testosterone, dihydrotestosterone and epidermal growth factor was measured by radioimmunoassay. In the patients treated with the extract, a significant reduction (P < 0.001) in the concentration of dihydrotestosterone (50%) and epidermal growth factor (50%), and a significant increase (P < 0.001) in testosterone levels (125%), were observed in the periurethral region.

Contraindications

Owing to its effects on androgen and estrogen metabolism, the use of Fructus Serenoae Repentis during pregnancy or lactation and in children under the age of 12 years is contraindicated.

Warnings

Fructus Serenoae Repentis relieves the symptoms associated with BPH, but does not have an effect on the size of the prostate. If symptoms worsen or do not improve, or in cases of blood in the urine or acute urinary retention, contact a physician.

News and Journals

References
1. Blumenthal M et al., eds. The complete German Commission E monographs. Austin, TX,
American Botanical Council, 1998.
2. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.
3. The United States pharmacopeia 24: national formulary 19. Rockville, MD, United States Pharmacopeial Convention, 1999.
4. Blaschek W et al., eds. Hagers Handbuch der pharmazeutischen Praxis. Folgeband 2: Drogen A–K, 5th ed. Berlin, Springer-Verlag, 1998.
5. Farnsworth NR ed. NAPRALERT database. Chicago, University of Illinois at Chicago,
IL, January 20, 1998 production (an online database available directly through the
University of Illinois at Chicago or through the Scientific and Technical Network
[STN] of Chemical Abstracts Services).
6. Gathercoal EN, Wirth EH. Pharmacognosy. Philadelphia, Lea & Febiger, 1936.
7. Hänsel R, Rimpler H, Schoepfliin G. Thin-layer chromatography of Sabal (saw palmetto)
fruits. Planta Medica, 1964, 12:169–172.
8. Quality control methods for medicinal plant materials. Geneva, World Health Organization, 1998.
9. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.
10. Guidelines for predicting dietary intake of pesticide residues. Geneva, World Health Organization, 1989.
11. De Swaef SI, Vlietinck AJ. Simultaneous quantitation of lauric acid and ethyl
laureate in Sabal serrulata by capillary gas chromatography and derivatisation with
trimethyl sulphonium hydroxide. Journal of Chromatography, 1996, 719:479–482.
12. Wajda-Dubois JP et al. Comparative study on the lipid fraction of pulp and seeds
of Serenoa repens (Palmaceae). Oleagineux Corps Gras Lipides, 1996, 3:136–139.
13. Hänsel R et al. Eine Dünnschichtchromatographische Untersuchung der Sabalfrüchte.
Planta Medica, 1964, 12:136–139.
14. Wilt TJ et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia.
A systematic review. Journal of the American Medical Association, 1998, 280:1604–1609.
15. Vahlensieck W et al. Benigne Prostatahyperplasie-Behandlung mit Sabalfrüchteextrakt.
Fortschritte der Medizin, 1993, 111:323–326.
16. Carraro JC et al. Comparison of phytotherapy (Permixon®) with finasteride in the
treatment of benign prostatic hyperplasia: a randomized international study of 1098
patients. Prostate, 1996, 29:231–240.
17. Bach D, Ebeling L. Long-term treatment of benign prostatic hyperplasia—results of
a prospective 3-year multicenter study using Sabal extract IDS 89. Phytomedicine, 1996, 3:105–111.
18. Braeckman J. The extract of Serenoa repens in the treatment of benign prostatic
hyperplasia: a multicenter open study. Current Therapeutic Research, 1994, 55: 776–786.
19. Schneider HJ, Uysal A. Internationaler Prostata-Symptomenscore (I-PSS) im klinischen
Alltag. Urologie [B], 1994, 34:443–447.
20. Braekman J et al. Efficacy and safety of the extract of Serenoa repens in the treatment
of benign prostatic hyperplasia: therapeutic equivalence between twice and once daily dosage forms. Phytotherapy Research, 1997, 11:558–563.
21. Derakhshani P et al. Beeinflussung des Internationalen Prostata-Symptomensore
unter der Therapie mit Sägepalmenfrüchteextrakt bei täglicher Einmalgabe. Urologie [B], 1997, 37:384–391.
22. Ziegler H, Hölscher U. Wirksamkeit des Spezialextraktes WS 1473 aus Sägepalmenfrüchteextrakt
bei Patienten mit benigner Prostatahyperplasie im Stadium I–II
nach Alken—offene Multicenter-Studie. Jatros Uro, 1998, 14:34–43.
23. Redecker KD, Funk P. Sabal-Extrakt WS 1473 bei benigner Prostatahyperplasie. Extracta Urologica, 1998, 21:23–25.
24. Hanusˇ M, Matousˇková M. Alternativní lécˇba BPH — Permixon (Capistan). Rozhledy Chirurgia, 1993, 72:75–79.
25. Romics I et al. Experience in treating benign prostatic hypertrophy with Sabal serrulata
for one year. Journal of International Urology and Nephrology, 1993, 25:565–569.
26. Boccafoschi C, Annoacia S. Confronto fra estratto di Serenoa repens e placebo mediante
prova clinica controllata in pazienti co adenmatosi prostatica. Urologia, 1983, 50:1–14.
27. Champault G et al. A double-blind trial of an extract of the plant Serenoa repens
in benign prostatic hyperplasia. British Journal of Clinical Pharmacology, 1984, 18:461–462.
28. Cukier C et al. Serenoa repens extract vs placebo. Comptes rendus de therapeutiques et
de Pharmacologie clinique, 1985, 4:15–21.
29. Descotes JL et al. Placebo-controlled evaluation of the efficacy and tolerability of
Permixon® in benign prostatic hyperplasia after exclusion of placebo responders.
Clinical Drug Investigations, 1995, 9:291–297.
30. Emili E et al. Clinical results on a new drug in the treatment of benign prostatic
hyperplasia (Permixon). Urologia, 1983, 50:1042–1049.
31. Tasca A et al. Treatment of obstruction in prostatic adenoma using an extract of
Serenoa repens. Double-blind clinical test vs placebo. Minerva Urologica e Nefrologica, 1985, 37:87–91.
32. Mandressi A et al. Treatment of uncomplicated benign prostatic hypertrophy (BPH)
by an extract of Serenoa repens: clinical results. Journal of Endocrinology Investigations, 1987, 10 (Suppl. 2):49.
33. Descotes JL et al. Placebo-controlled evaluation of the efficacy and tolerability of
Permixon in benign prostatic hyperplasia after exclusion of placebo responders.
Clinical Drug Investigations, 1995, 9:291–297.
34. Gutierrez M et al. Mechanisms involved in the spasmolytic effect of extracts from
Sabal serrulata fruit on smooth muscle. General Pharmacology, 1996, 27:171–176.
35. Odenthal KP, Rauwald HW. Lipophilic extract from Sabal serrulata inhibits contractions
in smooth muscle tissue. Aktuelle Urologie, 1996, 27:152–157.
36. Hiermann A. About the contents of Sabal fruits and their anti-inflammatory effect.
Archiv der Pharmazie (Weinheim), 1989, 322:111–114.
37. Koch E. Pharmakologie und Wirkmechanismen von Extrakten aus Sabalfrüchten
(Sabal fructus), Brennesselwurzeln (Urticae radix) und Kürbissamen (Curcurbitae
peponis semen) bei der Behandlung der benignen Prostatahyperplasie. In: Loew D,
Rietbrock N, eds. Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt, Steinkopff, 1995:57–79.
38. Tarayre JP et al. Anti-edematous action of a hexane extract from Serenoa repens Bartr.
drupes. Annales pharmaceutiques françaises, 1983, 41:559–570.
39. Breu W et al. Antiphlogistische Wirkung eines mit hyperkritischem Kohlendioxid
gewonnenen Sabalfrucht-Extraktes. Arzneimittel-Forschung, 1992, 42:547–551.
40. Paubert-Braquet M et al. Effect of the lipidic lipidosterolic extract of Serenoa repens
(Permixon®) on the ionophore A23187-stimulated production of leukotriene B4
(LTB4) from human polymorphonuclear neutrophils. Prostaglandins, Leukotrienes and
Essential Fatty Acids, 1997, 57:299–304.
41. Wagner H. Immunstimulierend wirkende Polysaccharide (Heteroglykane) aus
höheren Pflanzen. Arzneimittel-Forschung, 1985, 35:1069–1075.
42. El-Sheikh MM, Dakkak MR, Saddique A. The effect of Permixon® on androgen
receptors. Acta Obstetrics and Gynecology of Scandinavia, 1988, 67:397–399.
43. Sultan C et al. Inhibition of androgen metabolism and binding by a liposterolic
extract of “Serenoa repens B” in human foreskin fibroblasts. Journal of Steroid Biochemistry, 1984, 20:515–519.
44. Briley M, Carilla E, Fauran F. Permixon, a new treatment for benign prostatic hyperplasia,
acts directly at the cytosolic androgen receptor in rat prostate. British Journal of Pharmacology, 1983, 79:327.
45. Carilla E et al. Binding of Permixon, a new treatment for prostatic benign hyperplasia,
to the cytosolic androgen receptor in rat prostate. Journal of Steroid Biochemistry, 1984, 20:521–523.
46. Hagenlocher M et al. Specific inhibition of 5a-reductase by a new extract of Sabal
serrulata. Aktuelle Urologie, 1993, 24:146–149.
47. Di Silverio F et al. Evidence that Serenoa repens extract displays an antiestrogenic
activity in prostatic tissue of benign prostatic hypertrophy patients. European Urology 1992, 21:309–314.
48. Ravenna L et al. Effects of the lipidosterolic extract of Serenoa repens (Permixon®)
on human prostatic cell lines. Prostate, 1996, 29:219–230.
49. Niederprüm HJ et al. Testosterone 5a-reductase inhibition by free fatty acids from
Sabal serrulata fruits. Phytomedicine, 1994, 1:127–133.
50. Delos S et al. Testosterone metabolism in primary cultures of human prostate
epithelial cells and fibroblasts. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55:375–383.
51. Rhodes L et al. Comparison of finasteride (Proscar®), a 5a-reductase inhibitor, and
various commercial plant extracts in in vitro and in vivo 5a-reductase inhibition. Prostate, 1993, 22:43–51.
52. Iehle C et al. Human prostatic steroid 5a-reductase isoforms, a comparative study
of selective inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54: 273–279.
53. Weisser H et al. Effects of Sabal serrulata extract IDS 89 and its subfractions on 5areductase
activity in human benign prostatic hyperplasia. Prostate, 1996, 28:300–306.
54. Weisser H et al. Enzyme activities in tissue of human benign prostatic hyperplasia
(BPH) after three months of treatment with Sabal serrulata extract IDS 89 (Strogen)
or placebo. European Urology, 1997, 31:97–101.
55. Paubert-Braquet M et al. Effect of Serenoa repens extract (Permixon®) on estradiol/
testosterone-induced experimental prostate enlargement in the rat. Pharmacological Research, 1996, 34:171–179.
56. Otto U et al. Transplantation of human benign hyperplastic prostate tissue into nude
mice: first results of systemic therapy. Urologie Internationale, 1992, 48:167–170.
57. Paubert-Braquet M et al. Effect of the lipidosterolic extract of Serenoa repens
(Permixon) and its major components on basic fibroblast growth factor-induced
proliferation of cultures of human prostate biopsies. European Urology, 1998, 33: 340–347.
58. Vacher P et al. The lipidosterolic extract from Serenoa repens interferes with prolactin
receptor signal transduction. Journal of Biomedical Sciences, 1995, 2:357–365.
59. Goepel M et al. Saw palmetto extracts potently and noncompetitively inhibit human
a1-adrenoceptors in vitro. Prostate, 1999, 38:208–215.
60. Gabric V, Miskic H. Behandlung des benignen Prostataadenoms und der chronischen
Prostatitis. Therapiewoche, 1987, 37:1775–1788.
61. Reese-Smith H et al. The value of Permixon in benign prostatic hypertrophy. British Journal of Urology, 1986, 58:36–40.
62. Braeckman J et al. A double-blind, placebo-controlled study of the plant extract
Serenoa repens in the treatment of benign hyperplasia of the prostate. European Journal of Clinical Research, 1997, 9:247–259.
63. Helpap B et al. Morphology of benign prostatic hyperplasia after treatment with
sabal extract IDS 89 or placebo. Journal of Urology and Pathology, 1995, 3:175–182.
64. Di Silverio F et al. Effects of long-term treatment with Serenoa repens (Permixon®)
on the concentrations and regional distribution of androgens and epidermal growth
factor in benign prostatic hyperplasia. Prostate, 1998, 37:77–83.
65. Anderson JT. a1-Blockers vs 5a-reductase inhibitors in benign prostatic hyperplasia:
a comparative review. Drugs and Aging, 1995, 6:388–396.
66. Grasso M et al. Comparative effects of alfuzosin versus Serenoa repens in the treatment
of symptomatic benign prostatic hyperplasia. Archivos Espanoles de Urologia, 1995, 48:97–103.
67. Adriazola Semino M et al. Tratamiento sintomatico de la hipertrofia benigna de
prostata. Estudio comparativo entre Prazosin y Serenoa repens. Archivos Espanoles de Urologia, 1992, 45:211–213.
68. Bombardelli E, Morazzoni P. Serenoa repens (Bartram) J.K. Small. Fitoterapia, 1997, 68:99–113.
69. Lowe FC et al. Review of recent placebo-controlled trials utilizing phytotherapeutic
agents for treatment of BPH. Prostate, 1998, 37:187–193.
70. Plosker GL, Brogden RN. Serenoa repens (Permixon®). A review of its pharmacology
and therapeutic efficacy in benign prostatic hyperplasia. Drugs and Aging, 1996, 9: 379–395.
71. De Bernardi di Valserra M, Tripodi AS, Contos S. Serenoa repens capsules: a bioequivalence
study. Acta Toxicologia Therapeutica, 1994, 15:21–39.
72. Bernard P, Cousse H, Chevalier G. Distribution of radioactivity in rats after oral
administration of lipidosterolic extract of Serenoa repens (Permixon®) supplemented
with [1-14C]-lauric acid, [1-14C] oleic acid or [4-14C] beta-sitosterol. European Journal
of Drug Metabolism and Pharmacokinetics, 1997, 22:73–83